Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P-Y Dietrich

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
International Journal of Cancer|September 4, 1995
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivoF Farace, E Angevin, P Y Dietrich, et al.
Blood|August 15, 1994
Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?P Y Dietrich, M Henry-Amar, J M Cosset, et al.
Bulletin Du Cancer|October 1, 1996
[Treatment of aggressive non Hodgkin's lymphoma: the experience of a general hospital]F M Laurencet, G B Zulian, P Y Dietrich, et al.
The Journal of Investigative Dermatology|December 24, 1997
Transformed and nontransformed human T lymphocytes migrate to skin in a chimeric human skin/SCID mouse modelN Rosenblatt-Velin, J F Arrighi, P Y Dietrich, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancerE Angevin, D Valteau-Couanet, F Farace, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 1, 2014
Aggressiveness of cancer treatment in patients hospitalized in a supportive care unitC Luthy, A Pugliesi, E Rapiti, et al.
International Journal of Cancer|July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinomaF Farace, E Angevin, B Escudier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cellsP R Walker, T Calzascia, V Schnuriger, et al.
Revue Medicale Suisse|September 30, 2011
[Anticancer drugs under pressure]A Ben Aïssa, A-C George, F Z El M'Rabet, et al.
International Immunology|August 1, 1997
TCR analysis reveals significant repertoire selection during in vitro lymphocyte cultureP Y Dietrich, P R Walker, V Schnuriger, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
International Journal of Cancer|September 4, 1995
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivoF Farace, E Angevin, P Y Dietrich, et al.
Blood|August 15, 1994
Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?P Y Dietrich, M Henry-Amar, J M Cosset, et al.
Bulletin Du Cancer|October 1, 1996
[Treatment of aggressive non Hodgkin's lymphoma: the experience of a general hospital]F M Laurencet, G B Zulian, P Y Dietrich, et al.
The Journal of Investigative Dermatology|December 24, 1997
Transformed and nontransformed human T lymphocytes migrate to skin in a chimeric human skin/SCID mouse modelN Rosenblatt-Velin, J F Arrighi, P Y Dietrich, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancerE Angevin, D Valteau-Couanet, F Farace, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 1, 2014
Aggressiveness of cancer treatment in patients hospitalized in a supportive care unitC Luthy, A Pugliesi, E Rapiti, et al.
International Journal of Cancer|July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinomaF Farace, E Angevin, B Escudier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cellsP R Walker, T Calzascia, V Schnuriger, et al.
Revue Medicale Suisse|September 30, 2011
[Anticancer drugs under pressure]A Ben Aïssa, A-C George, F Z El M'Rabet, et al.
International Immunology|August 1, 1997
TCR analysis reveals significant repertoire selection during in vitro lymphocyte cultureP Y Dietrich, P R Walker, V Schnuriger, et al.
Pageof 8